List view / Grid view
The exciting potential of immunotherapy for cancer treatment continues its exploration and here, Drug Target Review investigates three of the latest pre-clinical developments in immuno-oncology research.
Scientists have showed that a three inhibitors (3i) cocktail could reprogramme fibroblasts to a naïve embryonic stem cell-like state and remove disease-associated epigenetic changes.
A research team have identified a protein that binds breast cancer cells together, allowing them to metastasise, which could be significant in the development of cancer therapies.
16 May 2019 | By
Researchers say they have affirmed inconsistencies in the use of a common laboratory procedure called immunohistochemical staining.
New methods of studying the evolution of treatment resistance in head and neck cancer are being developed by researchers at the Johns Hopkins Kimmel Cancer Center...
Researchers have discovered changes to five new regions in the human genome that may increase the risk of pancreatic cancer...
Researchers have developed a single blood test that screens for eight common cancer types and helps identify the location of cancer...
